Urinary bladder function in patients with overactive bladder syndrome and study of trospium chloride treatment effectiveness depending on urinary bladder changes. The effect of trospium chloride on the cognitive function of patients.

Urodynamic findings in patients with overactive bladder syndrome. Is there a difference in treatment effectiveness depending on urodynamic outcomes? The effect of trospium chloride on the cognitive function of patients.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17587199

Enrollment

Registered

2025-02-11

Start date

2010-01-17

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female patients complaining of symptoms of overactive bladder syndrome Urological and Genital Diseases

Interventions

• An independent pharmacist prepared and randomly assigned the medication or placebo, documenting each kit sequentially starting from number 1. At randomization, patients were assigned to one of the t

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Female patients 2. Aged over 18 years 3. Complaining of symptoms of overactive bladder syndrome (urgent urination—at least once a day, frequency of urination—more than 8 times per day, nocturia—more than once per night) with or without urgency urinary incontinence for at least 6 months 4. Not having received treatment with antimuscarinic medications for at least 2 weeks before the study start 5. No diagnosis of painful bladder syndrome 6. Bladder volume greater than 150 ml 7. Sufficiently informed and provided written consent for the use of research data 8. Adequate understanding of the Ukrainian language and ability to complete questionnaires 9. Not participating in any other clinical trials simultaneously

Exclusion criteria

Exclusion criteria: 1. The use of antimuscarinics or other medications affecting bladder activity within one month prior to entering the study 2. Participation in another OAB study 3. Painful bladder syndrome, known neurological disorders (e.g., paraplegia, multiple sclerosis, Parkinson’s disease, history of stroke) 4. Stress urinary incontinence (SUI), 5. Active urinary tract infection, confirmed through urine microscopy 6. Infravesical obstruction, grade II or higher vaginal prolapse, or obstructive voiding patterns

Design outcomes

Primary

Measure	Time frame
Trospium chloride effect is measured using the Overactive Bladder Symptoms Score and Overactive Bladder Symptoms Bother at baseline and 6 weeks	—

Secondary

Measure	Time frame
Cognitive function is measured using the Montreal Cognitive Assessment (MoCA) at baseline and 6 weeks	—

Countries

Ukraine

Contacts

Public ContactTaras Ptashnyk

t.ptashnyk@bbtgruppe.de+49 621 81020

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026